Company intelligence / Profile preview

Droplet Biosciences

Cambridge, Massachusetts, United Statesdropletbiosci.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Droplet Biosciences has developed a novel diagnostic platform that analyzes lymphatic fluid collected from surgical drains after tumor resection. This approach enables earlier and more sensitive detection of cancer recurrence compared to blood-based assays. The technology is currently being validated in clinical settings with an initial focus on head and neck cancers. No published pivotal trial results yet.

Therapeutic areas: Oncology
Modalities: Diagnostic assayLiquid biopsy (lymph liquid biopsy)
Industry: Molecular Diagnostics

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Droplet Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Droplet Biosciences.

Explore the full profile